Verbatim response from Claude
This is a fast-moving regulatory area, so I want to be straightforward with you:
Important Context First
The FDA declared the semaglutide shortage over in early 2025, which legally restricts most compounding of semaglutide (Ozempic/Wegovy). Tirzepatide (Mounjaro/Zepbound) shortage status has also changed.
Services That Have Been Navigating This Space
- Hims & Hers - Was offering compounded semaglutide but faced legal pressure; check their current status
- Ro (Body Program) - Similar situation, pivoting to brand-name options
- Henry - Has offered compounded options
- Mochi Health - Has worked with compounding pharmacies
Honest Caveats
- Many providers have had to stop or modify their compounded offerings due to FDA enforcement
- Services advertising compounded semaglutide may be operating in a legal gray area
- Formulations with added ingredients (B12, etc.) have different rules
My Recommendation
- Verify directly with any service before signing up - policies change monthly
- Ask specifically what pharmacy compounds it and their FDA compliance status
- Consider whether brand-name options with manufacturer coupons (like Eli Lilly's savings program) might be comparable in cost
Would you like help thinking through the brand-name alternatives instead?